Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Abstract | BACKGROUND: METHODS: In this randomised, double-blind, placebo-controlled trial ( SID-GBS), we included patients (≥12 years) with Guillain-Barré syndrome admitted to one of 59 participating hospitals in the Netherlands. Patients were included on the first day of standard intravenous immunoglobulin treatment (2 g/kg over 5 days). Only patients with a poor prognosis (score of ≥6) according to the modified Erasmus Guillain-Barré syndrome Outcome Score were randomly assigned, via block randomisation stratified by centre, to SID (2 g/kg over 5 days) or to placebo, 7-9 days after inclusion. Patients, outcome adjudicators, monitors, and the steering committee were masked to treatment allocation. The primary outcome measure was the Guillain-Barré syndrome disability score 4 weeks after inclusion. All patients in whom allocated trial medication was started were included in the modified intention-to-treat analysis. This study is registered with the Netherlands Trial Register, NTR 2224/NL2107. FINDINGS: Between Feb 16, 2010, and June 5, 2018, 327 of 339 patients assessed for eligibility were included. 112 had a poor prognosis. Of those, 93 patients with a poor prognosis were included in the modified intention-to-treat analysis: 49 (53%) received SID and 44 (47%) received placebo. The adjusted common odds ratio for improvement on the Guillain-Barré syndrome disability score at 4 weeks was 1·4 (95% CI 0·6-3·3; p=0·45). Patients given SID had more serious adverse events (35% vs 16% in the first 30 days), including thromboembolic events, than those in the placebo group. Four patients died in the intervention group (13-24 weeks after randomisation). INTERPRETATION: FUNDING: Prinses Beatrix Spierfonds and Sanquin Plasma Products.
|
Authors | Christa Walgaard, Bart C Jacobs, Hester F Lingsma, Ewout W Steyerberg, Bianca van den Berg, Alexandra Y Doets, Sonja E Leonhard, Christine Verboon, Ruth Huizinga, Judith Drenthen, Samuel Arends, Ilona Kleine Budde, Ruud P Kleyweg, Krista Kuitwaard, Marjon F G van der Meulen, Johnny P A Samijn, Frederique H Vermeij, Jan B M Kuks, Gert W van Dijk, Paul W Wirtz, Filip Eftimov, Anneke J van der Kooi, Marcel P J Garssen, Cees J Gijsbers, Maarten C de Rijk, Leo H Visser, Roderik J Blom, Wim H J P Linssen, Elly L van der Kooi, Jan J G M Verschuuren, Rinske van Koningsveld, Rita J G Dieks, H Job Gilhuis, Korné Jellema, Taco C van der Ree, Henriette M E Bienfait, Catharina G Faber, Harry Lovenich, Baziel G M van Engelen, Rutger J Groen, Ingemar S J Merkies, Bob W van Oosten, W Ludo van der Pol, Willem D M van der Meulen, Umesh A Badrising, Martijn Stevens, Albert-Jan J Breukelman, Casper P Zwetsloot, Maaike M van der Graaff, Marielle Wohlgemuth, Richard A C Hughes, David R Cornblath, Pieter A van Doorn, Dutch GBS Study Group |
Journal | The Lancet. Neurology
(Lancet Neurol)
Vol. 20
Issue 4
Pg. 275-283
(04 2021)
ISSN: 1474-4465 [Electronic] England |
PMID | 33743237
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Elsevier Ltd. All rights reserved. |
Chemical References |
- Immunoglobulins, Intravenous
|
Topics |
- Adult
- Aged
- Double-Blind Method
- Female
- Guillain-Barre Syndrome
(drug therapy)
- Humans
- Immunoglobulins, Intravenous
(administration & dosage)
- Male
- Middle Aged
- Netherlands
- Prognosis
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|